TSC1 and urinary bladder cancer: However, recent studies of TSC1 missense variants identified in bladder cancers [17] and in patients with TSC [11] have shown that TSC1 amino acid substitutions can be pathogenic, reducing steady state levels of TSC1 and leading to increased mTOR activity.